Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
CERS insider sale filings reported by Richard J. Benjamin. The filing shows sales of 24,235 common shares on 03/06/2026 for $48,603.19 and 61,233 common shares on 03/05/2026 for $126,299.19. A broker-dealer listed is Morgan Stanley Smith Barney LLC with a reference date of 03/09/2026. The record also references 40,426 common shares tied to restricted stock dated 03/06/2025.
Morgan Stanley Smith Barney LLC notified a proposed sale of common stock for issuer-restricted shares related to CERS. The notice lists proposed sale activity tied to restricted stock grants dated 03/12/2023 (43,092 shares) and 03/12/2024 (12,133 shares), and references an aggregate number 192,171,776.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of restricted common stock of the issuer CERS (NASDAQ). The filing lists 52,385 restricted shares dated 03/12/2024 and 8,848 restricted shares dated 03/12/2022.
Cerus Corp’s chief medical officer, Benjamin Richard J, reported an equity grant on Form 4. On March 2, 2026, he acquired 264,000 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he directly holds 949,775 common shares. Each RSU converts into one share and vests in two installments: 34% on March 12, 2027 and 66% on March 12, 2028, subject to his continuous service with Cerus through each vesting date.
Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an award of 300,000 restricted stock units, each representing one share of common stock. The grant was at no cash cost to him and increases his direct holdings to 1,187,262 shares, including prior employee stock purchase plan shares.
The RSUs vest in two stages: 34% on March 12, 2027 and 66% on March 12, 2028, conditioned on his continued service with the company through each vesting date.
Cerus Corp reported that President and CEO William Mariner Greenman received a grant of 1,200,000 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest with 34% on March 12, 2027 and 66% on March 12, 2028, contingent on his continued service. Following this equity award and recent employee stock purchase plan acquisitions, his direct holdings total 5,331,167 shares of Cerus common stock.
Jayaraman Vivek K reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an award of 420,000 restricted stock units representing common shares on March 2, 2026, at a stated price of $0.00 per share. These RSUs vest in two annual installments, with 34% vesting on March 12, 2027, and 66% vesting on March 12, 2028, contingent on his continuous service with the company through each vesting date.
After this grant, his directly held common stock, including shares from the company’s employee stock purchase plan, totals 1,866,648 shares. This total includes 5,318 shares purchased on August 29, 2025, and 10,004 shares purchased on February 27, 2026, under the employee stock purchase plan.
Jensen Chrystal reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp reported that Chief Legal Officer Chrystal Jensen received a grant of 300,000 shares of common stock in the form of restricted stock units. These RSUs vest in two steps: 34% on March 12, 2027 and 66% on March 12, 2028, contingent on continued service. After this award, Jensen directly holds 1,028,294 shares.
Cerus Corporation files its annual report describing its INTERCEPT blood safety business and development pipeline. The company sells pathogen-reduction systems for platelets, plasma and cryoprecipitation in the U.S. and multiple international markets, using proprietary compounds and UVA illumination to inactivate viruses, bacteria, parasites and leukocytes.
Cerus is investing heavily in an INTERCEPT red blood cell system, supported by BARDA and DoD contracts, with Phase 3 U.S. trials and a resubmitted MDR application in Europe after an earlier conformity assessment was closed. The filing highlights dependence on key suppliers and government funding, concentrated blood-center customers, extensive global regulation and the risk that the red cell program may never achieve approval or broad adoption, which could prolong operating losses.
Cerus Corporation reported strong 2025 growth with total revenue of $233.8 million, up 16% from 2024. Product revenue rose 14% to $206.1 million, helped by expansion of its INTERCEPT platelet franchise and higher U.S. INTERCEPT Fibrinogen Complex (IFC) sales.
IFC revenue increased about 80% to $16.7 million, and total product gross profit reached $112.3 million with a 54.5% margin, slightly below last year. Net loss narrowed to $15.6 million (or $0.08 per share), while non-GAAP adjusted EBITDA improved to $9.5 million. Cerus ended 2025 with $82.9 million in cash, cash equivalents and short-term investments and generated $4.8 million in operating cash flow for the year. For 2026, the company reaffirms product revenue guidance of $224–$228 million, implying 9%–11% growth, including expected IFC revenue of $20–$22 million, or roughly 20%–30% growth.